ArticleBMC cancer2025
Patient-reported symptom burden and health-related quality of life in patients with aggressive Non-Hodgkin lymphoma: a cross-sectional study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Using Q-Methodology to Identify Core Illness Experience Dimensions in Treated Lymphoma Patients.Current oncology (Toronto, Ont.) · 2026Article
- Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints.Current oncology (Toronto, Ont.) · 2026Article
- Effectiveness of Integrative Medicine in the Management of Lymphoma Survivors: An Exploratory Preference-Based Controlled Trial.Acta haematologica · 2026Article
- Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPatient-reported health-related quality of life (HRQoL) impacted by symptom burden is predictive of overall survival in patients with aggressive Non-Hodgkin lymphoma (NHL).
methodThis cross-sectional study investigated the Core Symptoms Burden Set (CSBS) significantly affecting the HRQoL in patient with aggressive NHL and identify a single cutoff point to separate clinical difference. The MDASI-TCM and EQ-5D-5 L were used to assess the symptom (severity and interference) and HRQoL. The t test, chi-square test or Wilcoxon rank-sum test were used to determine differences in symptoms burden between during and after cancer therapies. A multivariate linear regression model was used to identify associations between the CSBS and HRQoL. Receiver operating characteristic curves were used to identify optimum cutoff point considered the grading scale (0 vs. 1-3) of the ECOG as the anchor.
resultsTotal 116 eligible patients with aggressive NHL were analyzed. The CSBS were disturbed sleep (47.4%), fatigue (44.3%), and difficulty remembering (40.9%). The EQ-5D index value ranged from - 0.294 to 1.0 and the median of EQ VAS was 80(Interquartile: 25). There were 22.4% of patients with "11111" health state. The CSBS demonstrated significantly influence in the physical function (B = 0.442, 95%CI 0.260-0.623, P < 0.001), psychological function (B = 0.674, 95%CI 0.495-0.853, P < 0.001), EQ-5D index value (B = -0.014, 95%CI [-0.027]-[-0.001], P = 0.033) and EQ VAS (B = -3.047, 95%CI [-5.028]-[-1.066], P = 0.003) for the patients with aggressive NHL. The best cutoff point of CSBS with significantly clinical difference was 2.50, with a sensitivity of 82.4% and specificity of 64.6%.
conclusionsThe Core Symptoms Burden Set of patients with aggressive NHL impacted their HRQoL significantly whose score of 2.50 or higher would be a potential preliminary indicator to be emphasized and intervened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.